前列腺癌与反应性噬血细胞性淋巴组织细胞增生症
Prostate Cancer and Reactive Haemophagocytic Lymphohistiocytosis.
作者信息
Dumont Laura, Salaroli Adriano, Dal Lago Lissandra, Gil Thierry, Pepersack Thierry
机构信息
Medical Oncology Department, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Department of Hematology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
出版信息
Eur J Case Rep Intern Med. 2021 Apr 1;8(4):002425. doi: 10.12890/2021_002425. eCollection 2021.
UNLABELLED
We report the case of a 76-year-old man presenting with reactive haemophagocytic lymphohistiocytosis (rHLH) in the setting of disseminated prostate cancer. This often fatal syndrome must be diagnosed early in order to maximize survival. Treatment should be initiated whenever the clinical diagnosis is suspected, even if the HLH-2004 criteria are not met. The HScore is a useful diagnostic tool for rHLH. In case of neurological symptoms, an extensive assessment must be performed. The goal of this case report is to raise awareness of this rare syndrome among oncologists.
LEARNING POINTS
The association of prostate cancer and reactive haemophagocytic lymphohistiocytosis (rHLH) has rarely been described.This often fatal syndrome must be recognized early in order to start specific treatment and maximize survival.Specific treatment for rHLH must be accompanied by treatment of the triggering factors.
未标注
我们报告了一例76岁男性在播散性前列腺癌背景下出现反应性噬血细胞性淋巴组织细胞增生症（rHLH）的病例。这种通常致命的综合征必须尽早诊断以提高生存率。只要怀疑临床诊断，即使未满足HLH - 2004标准，也应开始治疗。HScore是rHLH的一种有用诊断工具。出现神经症状时，必须进行全面评估。本病例报告的目的是提高肿瘤学家对这种罕见综合征的认识。
学习要点
前列腺癌与反应性噬血细胞性淋巴组织细胞增生症（rHLH）的关联很少被描述。这种通常致命的综合征必须尽早识别，以便开始特异性治疗并提高生存率。rHLH的特异性治疗必须同时治疗触发因素。
Zotero 插件